The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of zoledronate on FMAU positron emission tomography (PET) scanning results in metastatic prostate cancer.
 
Omid Saeed Tehrani
No Relationships to Disclose
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Jawana Lawhorn-Crews
No Relationships to Disclose
 
Lance K. Heilbrun
No Relationships to Disclose
 
Kimberlee Dobson
No Relationships to Disclose
 
Daryn W. Smith
No Relationships to Disclose
 
Brenda Dickow
Consulting or Advisory Role - Bayer; Novartis
 
Anthony Frank Shields
Stock and Other Ownership Interests - Radiology Corporation of America
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Perceptive Informatics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical
Speakers' Bureau - GE Healthcare
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Endocyte; GE Healthcare; Merrimack